Evidence map›Paper›PMID 42392696›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Andrea Farolfi, Caterina Maria Paola Sgro, Irene Brusa, Daniele Dall'Olio, Francesco Romei, Massimiliano Presutti, Matteo Droghetti, Andrea Di Giorgio, Riccardo Mei, Beniamino Corcioni and 6 more

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrea FarolfiNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; andrea.farolfi3@gmail.com.
Caterina Maria Paola SgroNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Irene BrusaNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Daniele Dall'OlioDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Francesco RomeiDepartment of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Massimiliano PresuttiDepartment of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Matteo DroghettiDepartment of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Andrea Di GiorgioNuclear Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy; and.
Riccardo MeiNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Beniamino CorcioniDepartment of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Caterina GaudianoDepartment of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Cristina MosconiDepartment of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Riccardo SchiavinaDepartment of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Paolo CastellucciNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Stefano FantiNuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Lorenzo BianchiDepartment of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) PET/CT may enhance detection of clinically significant prostate cancer (csPCa) in men with negative or equivocal multiparametric MRI (mpMRI), a setting where diagnostic uncertainty persists. This study assessed the diagnostic performance of PSMA PET/CT-guided targeted biopsy (PET-TB) versus systematic biopsy (SB) and explored the value of semiquantitative (SUV

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIImage-Guided BiopsyMultiparametric Magnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstatic NeoplasmsWhole Body ImagingAgedHumansMaleMiddle AgedProspective StudiesAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IImpMRI-negativeprostate cancerPSMA PET/CTtargeted biopsytotal-body PET

Identifiers

PMID42392696
PMCPMC13544197

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.